Remove 2029 Remove Diabetes Remove Dosage
article thumbnail

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Pharmaceutical Technology

Originally granted approval in its largest market, the US, in 2017, Ozempic has subsequently obtained approval for three distinct dosages, 0.5mg, 1.0mg, and 2.0mg, for the treatment of type 2 diabetes. This represents a significant 83% increase in sales between 2022–2029, demonstrating a compound annual growth rate (CAGR) of 9%.

article thumbnail

Top Performing Drug of 2021 - Trulicity (February Edition)

PharmaShots

Active Ingredient: dulaglutide Dosage Forms & Strengths: Injection: 0.75 Active Ingredient: dulaglutide Dosage Forms & Strengths: Injection: 0.75 To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.